SHAREHOLDER ALERT: Securities Class Action Lawsuit Against Cempra Announced By Holzer & Holzer; Firm Investigating Expanded Class Period

Holzer & Holzer, LLC announces that a securities class action lawsuit has been filed against Cempra, Inc. ("Cempra" or the "Company") (NASDAQ: CEMP) on behalf of investors who purchased its common stock between May 1, 2016 and November 1, 2016. The firm is investigating whether shareholders who purchased CEMP between October 22, 2015 and April 30, 2016 should also be included in the case.

The lawsuit alleges Cempra omitted material facts when discussing its lead product candidate, solithromycin. On November 2, 2016, the US Food and Drug Administration posted a preliminary review of solithromycin, which noted the developmental drug potentially posed a safety risk for hepatotoxicity. The price of CEMP stock fell dramatically fallowing the announcement.

If you purchased Cempra common stock between October 22, 2015 and November 1, 2016 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Marshall P. Dees, Esq., at mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832. Investors who wish to file a motion to become the lead plaintiff in the litigation must do so not later than January 3, 2017.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

If you liked this article you might like

Biotech Premarket Movers: Cempra, Tesaro, Editas

Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez

Biotech Premarket Movers: Cempra, Novavax, Ionis

Biotech Premarket Movers: BioCryst, Sangamo, Cempra